Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-03-13

Clinical Trial Update: Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 trial update for ABI-007 in preventing vascular access graft failure in hemodialysis patients; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABI-007 (nab-paclitaxel)

Snippet

Sponsor: Celgene | Conditions: Hemodialysis Graft Dysfunction | Phase 2 | Status: TERMINATED | Results posted: 2012-03-13